OBJECTIVE： Anti-asthma herbal medicine intervention （ASHMITM）, a combination of three tradi- tional Chinese medicinal herbs developed in our laboratory, has demonstrated efficacy in both mouse models of allergic as...OBJECTIVE： Anti-asthma herbal medicine intervention （ASHMITM）, a combination of three tradi- tional Chinese medicinal herbs developed in our laboratory, has demonstrated efficacy in both mouse models of allergic asthma, and a double-blind placebo-controlled clinical trial in patients with asthma. This study was designed to determine if the anti-inflammatory effects of individual herbal constituents of ASHMITM exhibited synergy. METHODS： Effects of ASHMI and its components aqueous extracts of Lingzhi （Ganoderma lucidum）, Kushen （Sophora flavescens） and Gancao （Glycyrrhiza uralensis）, on Th2 cytokine secretion by murine memory Th2 cells （D10.G4.1） and eotaxin-1 secretion by human lung fibroblast （HLF-1） cells were determined by measuring levels in culture supernatants by enzyme- linked immunosorbent assay. Potential synergistic effects were determined by computing interaction indices from concentration-effect curve parameters. RESULTS： Individual Lingzhi, Kushen and Gancao extracts and ASHMI （the combination of individual extracts） inhibited production of interleukin （IL）-4 and IL-5 by murine memory Th2 cells and eotaxin-1 production by HLF-1 cells. The mean 25%-inhibitory-concentration （IC2s） values （mg/mL） forASHMI, Lingzhi, Kushen and Gancao for IL-4 production were 30.9, 79.4, 123, and 64.6, respectively; for IL-5 production were 30.2, 263, 123.2 and 100, respectively; for eotaxin-1 were 13.2, 16.2, 30.2, and 25.1, respectively. The IC50values （mg/mL） for ASHMI, Lingzhi, Kushen and Gancao for IL-4 production were 158.5, 239.9, 446.7, and 281.8, respectively; for eotaxin-1 were 38.1, 33.1, 100, and 158.5, respectively. The interaction indices of ASHMI constituents at IC25 were 0.35 for IL-4, 0.21 for IL-5 and 0.59 for eotaxin-l. The interaction indices at IC^0 values were 0.50 for IL-4 and 0.62 for eotaxin-1 inhibition. Inhibition of IL-5 did not reach IC^0 values. All interaction indices were below 1 which indicated synergy. CONCLUSION： By comparing the interaction index values, we find that constituents in ASHMITM synergistically inhibited eotaxin-1 production as well as Th2 cytokine production.展开更多
目的:基于网络药理学方法筛选固本平喘剂(补骨脂、地龙、防风)中的主要活性成分,探讨其治疗支气管哮喘的作用机制。方法:通过中药系统药理学数据库TCMSP数据库、中药与化学成分数据库,筛选固本平喘剂的活性成分及靶标。利用Genecards、O...目的:基于网络药理学方法筛选固本平喘剂(补骨脂、地龙、防风)中的主要活性成分,探讨其治疗支气管哮喘的作用机制。方法:通过中药系统药理学数据库TCMSP数据库、中药与化学成分数据库,筛选固本平喘剂的活性成分及靶标。利用Genecards、OMIM数据库获得支气管哮喘的潜在靶标基因。将两者靶基因进行映射后通过Cytoscape3.6.1软件构建“成分-靶标”网络、结合String数据库构建蛋白质相互作用网络扩充核心靶点。依托功能注释生物信息学分析平台DAVID数据库对固本平喘剂的作用靶点进行基因本体(gene ontology,GO)生物学过程和基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)通路富集注释分析,通过Autodock vina软件进行分子对接以验证结果。结果:符合筛选条件的共有53个活性成分,补骨脂18个,地龙17个,防风18个,筛选得到固本平喘剂关键成分,包括补骨脂黄酮类、补骨脂查耳酮类、汉黄芩素、补骨脂酚、β-谷甾醇等;通过GenCards、OMIM数据库剔除重复后,共收集支气管哮喘潜在靶点2358个。将固本平喘剂和支气管哮喘靶点进行映射取交集共得到237个交叉靶点,即固本平喘剂治疗支气管哮喘潜在作用靶点。以degree值大于二倍均值的靶点为PTGS2、ESR1、ACHE、ESR2、PTGS1、DPP4、ADORA3,degree值排名前5的靶蛋白为PIK3CA、MAPK3、MAPK1、TP53、AKT1。主要涉及PI3K-Akt信号通路、TNF信号通路、趋化因子信号通路、FoxO信号通路、MAPK信号通路、Toll样受体信号通路、T细胞受体信号通路等。结论:固本平喘剂治疗支气管哮喘潜在作用靶点有PTGS2、ESR1、ACHE、ESR2、PTGS1、DPP4、ADORA3、PIK3CA、MAPK3、MAPK1、TP53、AKT1,可能通过抗感染、调节免疫、抑制气道重塑等发挥作用。展开更多
We evaluated the potential of orally fed new food formulations to inhibit biomarkers reported to be involved in the causes of allergic asthma in mice. Asthma, a serious non-communicable disease, affects both adults an...We evaluated the potential of orally fed new food formulations to inhibit biomarkers reported to be involved in the causes of allergic asthma in mice. Asthma, a serious non-communicable disease, affects both adults and children and can be undertreated. New functional foods could provide therapeutic approaches. Here, the anti-asthma mechanism of a new functional food and three isolated fractions produced by bioprocessing black rice bran with shiitake mushroom mycelia was evaluated in mast cells, B cells, and orally fed mice and compared with non-bioprocessed black rice bran. In vitro, the treatments inhibited RBL-2H3 cell degranulation and immunoglobulin E (IgE) production. The in vitro anti-asthma effects were confirmed in orally fed mice following asthma induction by alumina and chicken egg ovalbumin (OVA). The suppression of asthma resulted from the inhibition of inflammation- and immune-related substances, including OVA-specific IgE, thymic stromal lymphopoietin, eotaxin, leukotriene C4, prostaglandin D2, and vascular cell adhesion molecule-1 in bronchoalveolar lavage fluid and serum. The treatment also reversed the thickening of the lung airway wall. The inflammation and asthma inhibition seems to be regulated by the balance of the T-helper cells’ Th1/Th2 immune response and the inhibition of multiple biomarkers associated with the cause of asthma. Future human clinical studies with adults and children should determine the potential therapeutic value of the anti-asthma effects of the new functional foods.展开更多
基金supported by NIH/NCCAM center grant # 1P01 AT002644725-01"Center for Chinese Herbal Therapy(CHT) for Asthma"to Dr.Xiu-Min Li
文摘OBJECTIVE： Anti-asthma herbal medicine intervention （ASHMITM）, a combination of three tradi- tional Chinese medicinal herbs developed in our laboratory, has demonstrated efficacy in both mouse models of allergic asthma, and a double-blind placebo-controlled clinical trial in patients with asthma. This study was designed to determine if the anti-inflammatory effects of individual herbal constituents of ASHMITM exhibited synergy. METHODS： Effects of ASHMI and its components aqueous extracts of Lingzhi （Ganoderma lucidum）, Kushen （Sophora flavescens） and Gancao （Glycyrrhiza uralensis）, on Th2 cytokine secretion by murine memory Th2 cells （D10.G4.1） and eotaxin-1 secretion by human lung fibroblast （HLF-1） cells were determined by measuring levels in culture supernatants by enzyme- linked immunosorbent assay. Potential synergistic effects were determined by computing interaction indices from concentration-effect curve parameters. RESULTS： Individual Lingzhi, Kushen and Gancao extracts and ASHMI （the combination of individual extracts） inhibited production of interleukin （IL）-4 and IL-5 by murine memory Th2 cells and eotaxin-1 production by HLF-1 cells. The mean 25%-inhibitory-concentration （IC2s） values （mg/mL） forASHMI, Lingzhi, Kushen and Gancao for IL-4 production were 30.9, 79.4, 123, and 64.6, respectively; for IL-5 production were 30.2, 263, 123.2 and 100, respectively; for eotaxin-1 were 13.2, 16.2, 30.2, and 25.1, respectively. The IC50values （mg/mL） for ASHMI, Lingzhi, Kushen and Gancao for IL-4 production were 158.5, 239.9, 446.7, and 281.8, respectively; for eotaxin-1 were 38.1, 33.1, 100, and 158.5, respectively. The interaction indices of ASHMI constituents at IC25 were 0.35 for IL-4, 0.21 for IL-5 and 0.59 for eotaxin-l. The interaction indices at IC^0 values were 0.50 for IL-4 and 0.62 for eotaxin-1 inhibition. Inhibition of IL-5 did not reach IC^0 values. All interaction indices were below 1 which indicated synergy. CONCLUSION： By comparing the interaction index values, we find that constituents in ASHMITM synergistically inhibited eotaxin-1 production as well as Th2 cytokine production.
文摘目的:基于网络药理学方法筛选固本平喘剂(补骨脂、地龙、防风)中的主要活性成分,探讨其治疗支气管哮喘的作用机制。方法:通过中药系统药理学数据库TCMSP数据库、中药与化学成分数据库,筛选固本平喘剂的活性成分及靶标。利用Genecards、OMIM数据库获得支气管哮喘的潜在靶标基因。将两者靶基因进行映射后通过Cytoscape3.6.1软件构建“成分-靶标”网络、结合String数据库构建蛋白质相互作用网络扩充核心靶点。依托功能注释生物信息学分析平台DAVID数据库对固本平喘剂的作用靶点进行基因本体(gene ontology,GO)生物学过程和基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)通路富集注释分析,通过Autodock vina软件进行分子对接以验证结果。结果:符合筛选条件的共有53个活性成分,补骨脂18个,地龙17个,防风18个,筛选得到固本平喘剂关键成分,包括补骨脂黄酮类、补骨脂查耳酮类、汉黄芩素、补骨脂酚、β-谷甾醇等;通过GenCards、OMIM数据库剔除重复后,共收集支气管哮喘潜在靶点2358个。将固本平喘剂和支气管哮喘靶点进行映射取交集共得到237个交叉靶点,即固本平喘剂治疗支气管哮喘潜在作用靶点。以degree值大于二倍均值的靶点为PTGS2、ESR1、ACHE、ESR2、PTGS1、DPP4、ADORA3,degree值排名前5的靶蛋白为PIK3CA、MAPK3、MAPK1、TP53、AKT1。主要涉及PI3K-Akt信号通路、TNF信号通路、趋化因子信号通路、FoxO信号通路、MAPK信号通路、Toll样受体信号通路、T细胞受体信号通路等。结论:固本平喘剂治疗支气管哮喘潜在作用靶点有PTGS2、ESR1、ACHE、ESR2、PTGS1、DPP4、ADORA3、PIK3CA、MAPK3、MAPK1、TP53、AKT1,可能通过抗感染、调节免疫、抑制气道重塑等发挥作用。
文摘We evaluated the potential of orally fed new food formulations to inhibit biomarkers reported to be involved in the causes of allergic asthma in mice. Asthma, a serious non-communicable disease, affects both adults and children and can be undertreated. New functional foods could provide therapeutic approaches. Here, the anti-asthma mechanism of a new functional food and three isolated fractions produced by bioprocessing black rice bran with shiitake mushroom mycelia was evaluated in mast cells, B cells, and orally fed mice and compared with non-bioprocessed black rice bran. In vitro, the treatments inhibited RBL-2H3 cell degranulation and immunoglobulin E (IgE) production. The in vitro anti-asthma effects were confirmed in orally fed mice following asthma induction by alumina and chicken egg ovalbumin (OVA). The suppression of asthma resulted from the inhibition of inflammation- and immune-related substances, including OVA-specific IgE, thymic stromal lymphopoietin, eotaxin, leukotriene C4, prostaglandin D2, and vascular cell adhesion molecule-1 in bronchoalveolar lavage fluid and serum. The treatment also reversed the thickening of the lung airway wall. The inflammation and asthma inhibition seems to be regulated by the balance of the T-helper cells’ Th1/Th2 immune response and the inhibition of multiple biomarkers associated with the cause of asthma. Future human clinical studies with adults and children should determine the potential therapeutic value of the anti-asthma effects of the new functional foods.
